Insulet Forges Two Commercial Partnerships to Support its European Expansion

Insulet Corporation, developer of tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), has entered into partnerships with two highly-experienced diabetes distributors, Theras Group and Nordic Infucare, to provide full-service distribution of the Omnipod System in Italy and the Nordic markets beginning July 1. These partnerships are key milestones for Insulet’s transition to direct operations in Europe to fully support its Omnipod System.
 
“There are considerable commercial opportunities for the Omnipod System in Italy and the Nordics and we are thrilled to work with these two highly-experienced and respected diabetes medical device companies that have provided support to the local diabetes communities for many years,” said D.J. Cass, general manager, Europe. “Establishing these partnerships is another critical step forward to ensure Insulet’s smooth transition to direct operations in Europe and provides a platform for long-term growth and an exceptional customer experience.”
 
“Omnipod is a perfect fit within our existing diabetes portfolio and we are excited to partner with Insulet to provide support to Omnipod System users in Sweden, Norway, Denmark and Finland and to continue building awareness and knowledge of this unique insulin pump across our region,” said Mats Durvall, general manager, Nordic Infucare.
 
“We are also delighted to add the Omnipod System, the leading tubeless insulin pump technology, to our diabetes portfolio so we can offer greater options and support for people living with diabetes in Italy,” said Cristiano Ferrari, president of Theras Group.
 
Under the agreements, Theras Group and Nordic Infucare will provide sales, marketing and customer support for Omnipod System users and healthcare professionals.
 
The Omnipod Insulin Management System is a continuous insulin delivery system that provides all the proven benefits of continuous subcutaneous insulin infusion (CSII) therapy in a way no conventional insulin pump can. The Omnipod System’s innovative design and features allows people living with diabetes to live their life—and manage their diabetes—with unprecedented freedom, comfort, convenience, and ease. The Omnipod System consists of two components: (i) a Pod that stores and delivers insulin; and (ii) a Personal Diabetes Manager (PDM) that wirelessly programs the user’s personalized insulin delivery, calculates suggested doses and insulin on board, and has a convenient, built-in blood glucose meter. The small, light-weight Pod can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back and, because it is waterproof (IPX8), there is no need to remove when showering, swimming or performing other activities. This means that Omnipod can provide up to three days of non-stop insulin delivery, without the need to disconnect a tube set or manually inject insulin. The Pod and PDM communicate wirelessly to offer precise, personalized and continuous insulin delivery with customizable basal and bolus delivery options, as well as important safety checks. The Pod’s auto-cannula insertion is quick, simple, and virtually pain-free. Users never have to handle a needle. The user simply pushes a button on the PDM and the Pod’s automated insertion system inserts the cannula beneath the skin and begins delivering insulin according to the user’s programmed basal rate.
 
The Omnipod System is the world’s first commercially available tubeless insulin delivery system that allows users to live untethered by tubing and without the stress and anxiety of multiple daily injections. By breaking down the barriers to insulin pump therapy, the Omnipod System offers freedom for users to live life on their own terms and with the ease of use they deserve.
 
Insulet Corporation, headquartered in Massachusetts, has developed the Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives.
 
*Starting July 1, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it already does in the United States and Canada.